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Abstract
Objectives
To evaluate the prevalence of transmitted drug resistance (TDR) and non-B subtypes in pa-
tients with acute/recent HIV-1 infection in Barcelona during the period 1997-2012.
Methods
Patients from the “Hospital Clínic Primary HIV-1 Infection Cohort”with a genotyping test per-
formed within 180 days of infection were included. The 2009 WHO List of Mutations for Sur-
veillance of Transmitted HIV-1 Drug Resistance was used for estimating the prevalence of
TDR and phylogenetic analysis for subtype determination.
Results
189 patients with acute/recent HIV-1 infection were analyzed in 4 time periods (1997-2000,
n=28; 2001-4, n=42; 2005-8, n=55 and 2009-12, n=64). The proportion of patients with
acute/recent HIV-1 infection with respect to the total of newly HIV-diagnosed patients in our
center increased over the time and was 2.18%, 3.82%, 4.15% and 4.55% for the 4 periods,
respectively (p=0.005). The global prevalence of TDR was 9%, or 17.9%, 9.5%, 3.6% and
9.4% by study period (p=0.2). The increase in the last period was driven by protease-inhibi-
tor and nucleoside-reverse-transcriptase-inhibitor resistance mutations while non-nucleo-
side-reverse-transcriptase inhibitor TDR and TDR of more than one family decreased. The
overall prevalence of non-B subtypes was 11.1%, or 0%, 4.8%, 9.1% and 20.3 by study pe-
riod (p=0.01). B/F recombinants, B/G recombinants and subtype F emerged in the last
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period. We also noticed an increase in the number of immigrant patients (p=0.052). The pro-
portion of men-who-have-sex-with-men (MSM) among patients with acute/recent HIV-1 in-
fection increased over the time (p=0.04).
Conclusions
The overall prevalence of TDR in patients with acute/recent HIV-1 infection in Barcelona
was 9%, and it has stayed relatively stable in recent years. Non-B subtypes and immigrants
proportions progressively increased.
Introduction
Antiretroviral therapy (ART) has dramatically changed the natural history of HIV infection.
Most naïve patients who begin ART today suppress viral replication and achieve functional res-
toration of the immune system. However, during treatment, almost one-quarter of patients ex-
perience virological failure and often have resistant HIV isolates [1]. The widespread use of
ART and the increased survival of patients receiving it make the transmission of resistant HIV
strains likely to occur. Resistant strains have been reported in infections acquired through sex-
ual contact, vertical transmission and exposure to infected blood [2, 3]. Thus, transmitted drug
resistance (TDR) has become a relevant public health problem. Active surveillance of TDR pro-
vides important information about the factors involved in the transmission of resistant HIV
strains and in the selection of ART components. It plays a major role in the design of strategies
to control the evolution and emergence of resistance [4].
Worldwide, the prevalence of resistance in acute or recent HIV-1 infections ranges from 5%
to 24.5%[2, 5]. In Spain, the multicenter studies performed have very small samples [6, 7], and
there are no previous reports from Barcelona.
HIV-1 subtype B infections have traditionally been predominant among the infected Euro-
pean population, particularly in men-who-have-sex-with-men (MSM). However, the preva-
lence of non-B subtypes is increasing in developed countries, as result of international travel
and population migration [8, 9].
The aims of this study were to estimate the prevalence of antiretroviral resistance mutations
and non-B subtypes in a cohort of 189 consecutive patients with acute or recent HIV-1 infec-
tion in a tertiary teaching hospital in Barcelona, Spain, and to describe the pattern of changes
over a 16-year period (1997–2012).
Materials and Methods
Study population
The study population comprised patients from the “Hospital Clinic Primary HIV-1 Infection
Cohort” consecutively evaluated within 180 days after HIV infection at the Hospital Clínic, Bar-
celona, Spain, between January 1, 1997 and December 31, 2012. The inclusion criteria were de-
tectable viremia with a negative HIV serology result or documented seroconversion within the 6
months prior to the first evaluation. In symptomatic patients with several exposures, the date of
infection was assumed to be 14 days before the beginning of symptoms. For asymptomatic sero-
converters, the date of infection was assumed to be the midpoint between the last negative test
result and the first positive one. At the time of genotyping, patients with an estimated time of in-
fection of less than 30 days were defined as ‘acute infection’ and those with an estimated time of
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infection between 30 and 180 days as ‘recent infection’. Patients with resistance tests performed
beyond 180 days after the suspected day of infection were excluded from the analysis.
Patients were classified into 4 periods according to the year of diagnosis: 2009–2012 (wide-
spread availability in Barcelona of 4 new drugs: darunavir, etravirin, raltegravir and maraviroc)
and three earlier periods of equal duration: 1997–2000, 2001–2004 and 2005–2008.
Virological analyses
HIV serology was determined using a microparticle enzyme immunoassay (AxSYM, Abbott
Laboratories, Illinois, USA) and confirmed by line immunoassay (Inno-LIA HIV I/II Score,
Innogenetics, Ghent, Belgium). Viremia was measured using the Cobas Amplicor Monitor
(Roche Molecular Systems, Branchburg, New Jersey, USA) or the Versant HIV-1 RNA 1.0
Assay kPCR (Siemens Healthcare, Erlangen, Germany) with a limit of detection of 50 or 37 cop-
ies/mL, respectively. Genotypic mutations of both the reverse transcriptase gene and the prote-
ase gene from viral RNA were detected using the ViroSeq HIV Genotyping System v.2 (Abbott
Laboratories, Illinois, USA) and an ABI3100 sequencer. HIV- 1 subtype characterization was
first performed by using the REGA HIV-1 Subtyping Tool of the Stanford database (available
from http://dbpartners.stanford.edu/RegaSubtyping/) and confirmed by Neighbor-Joining (NJ)
phylogenetic analyses by using the MEGA version 6 program [10]. NJ phylogenetic trees were
inferred under the Kimura 2-parameter (K2-P) nucleotide substitution model and reliability of
the obtained tree topology was estimated with the bootstrap method with reference sequences
obtained from the HIV Sequence Database, Los Alamos National Laboratory (LANL; www.hiv.
lanl.gov). HIV-1 sequences suspected to be recombinants in the NJ phylogenetic tree were ana-
lyzed by bootscan analyses with Simplot 3.5.1 software [11]. The amino acid substitutions se-
lected by highly active antiretroviral therapy (HAART) and associated with drug resistance
were identified using the 2009World Health Organization (WHO) list of mutations for surveil-
lance of drug resistance [12]. Drug mutations for integrase inhibitors were not analyzed since
they are not routinely performed for patients with primary infection in our institution. Muta-
tions not included in the 2009WHO list, but associated with resistance to rilpivirine according
to Stanford HIV drug resistance database were also reported due to the clinical relevance.
Statistical analysis
The chi-square test or the Fisher exact test was used, as appropriate, to compare categorical
variables, and the Mann-Whitney or Klustal-Wallis tests were used, as appropriate, to compare
continuous variables. Links between resistant genotype and sex, age, risk factors, symptoms,
CD4 and CD8 cell counts, and viral load were tested. All p values were considered significant
at<0.05. As described above, 4 time periods were analyzed: 1997–2000, 2001–4, 2005–8 and
2009–12. The correlation between the increase in non-B HIV-1 subtypes and the increase in
immigration during the 4 study periods was evaluated using Spearman’s Rank Correlation Co-
efficient. All statistical analyses were performed using SPSS software, version 17.
The study was approved by the Institutional Review Board (Hospital Clínic-Institut d’Investiga-
cions Biomèdiques August Pi-Sunyer-IDIBAPS-). All patients signed the informed consent form.
Results
Patient characteristics according to analyzed periods
During the study period, 5,109 newly diagnosed patients underwent a first evaluation at our cen-
ter; of these, 199 (3.89%) met the criteria for primary HIV infection (PHI) and were enrolled in
the “Hospital Clínic Primary HIV-1 Infection Cohort”. Ten patients were excluded due to the
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genotypic resistance test being performed beyond 180 days post-infection; thus 189 patients
were included in the final analysis. Baseline characteristics of the whole population studied and
according to periods are described in Table 1: 92.6% were male, median (interquartile range) age
was 33 (28–39) years; for 81%, the main route of transmission was sexual relations between
MSM, and 31.2% were immigrants, most of whom from Latin America (56%), followed by other
Western European countries (15%) and Eastern European countries (10%). There were no pa-
tients from Sub-Saharan Africa. According to the predefined analyzed periods, 28 patients were
Table 1. Baseline characteristics of patients and study periods.
Period
total 1997–2000 2001–2004 2005–2008 2009–2012 p
N (%) 189 (100) 28 (14.8) 42 (22.2) 55 (29.1) 64 (33.9)
Gender* 0.011
Male 175 (92.6) 26 (92.9) 34 (81) 53 (96.4) 62 (96.9)
Female 14 (7.4) 2 (7.1) 8 (19) 2 (3.6) 2 (3.1)
Age** (n = 188) 33 (28–39) 30 (26–36) 31 (27–37) 34 (28–38) 34 (27–39) 0.275
<30* 63 (33.5) 13 (46.4) 16 (38.1) 14 (25.5) 20 (31.7)
30–40 82 (43.6) 10 (35.7) 20 (47.6) 27 (49.1) 25 (39.7)
40–50 33 (17.6) 3 (10.7) 4 (9.5) 12 (21.8) 14 (22.2)
>50 10 (5.3) 2 (7.1) 2 (4.8) 2 (3.6) 4 (6.3)
Route of transmission* 0.004
MSM-bisexual 153 (81) 21 (75) 30 (71.4) 47 (85.5) 55 (85.9)
Heterosexual 21 (11.1) 2 (7.1) 8 (19) 6 (10.9) 5 (7.8)
IDU 10 (5.3) 5 (17.9) 4 (9.5) 1 (1.8) 0 (0)
Unknown 5 (2.6) 0 (0) 0 (0) 1 (0) 4 (6.3)
Origin* 0.052
Native 120 (63.5) 24 (85.7) 24 (57.1) 36 (65.5) 36 (56.3)
Immigrant 59 (31.2) 2 (7.1) 14 (33.3) 18 (32.7) 25 (39.1)
Unknown 10 (5.3) 2 (7.1) 4 (9.5) 1 (1.8) 3 (4.7)
Symptomatic* 0.626
yes 162 (85.7) 23 (82.1) 34 (81) 49 (89.1) 56 (87.5)
no 27 (14.3) 5 (17.9) 8 (19) 6 (10.9) 8 (12.5)
Plasma HIV-1 log10RNA** (n = 188) 5.17 (4.51–5.80) 5.04 (4.39–5.80) 5 (4.43–5.40) 5.45 (4.75–5.62) 5.41 (4.50–5.89) 0.168
<5.0* 78 (41.5) 13 (46.4) 21 (50) 19 (35.2) 25 (39.1)
>5.0 110 (58.5) 15 (53.6) 21 (50) 35 (64.8) 39 (60.9)
CD4 cell count/ul** (n = 188) 494 (375–619) 494 (376–637) 584 (438–740) 506 (377–618) 402 (309–562) 0.009
<350 45 (23.9) 6 (21.4) 8 (19) 10 (18.5) 21 (32.8)
350–500 52 (27.7) 8 (28.6) 8 (19) 15 (27.8) 21 (32.8)
>500 91 (48.4) 14 (50) 26 (61.9) 29 (53.7) 22 (34.4)
Acute or Recent infection at genotyping* 0.21
Acute (infection of <30 days) 23 (12.2) 2 (7.2) 1 (2.4) 9 (16.4) 11 (17.2)
Recent (infection between 30 and 180 days) 166 (87.8) 26 (92.8) 41 (97.6) 46 (83.6) 53 (82.8)
Resistant strain (any mutation)* 17 (9) 5 (17.9) 4 (9.5) 2 (3.6) 6 (9.4) 0.2
Non-B subtypes* 20 (10.6) 0 (0) 2 (4.8) 5 (9.1) 13 (20.3) 0.01
* n(%)
** median (IQR)
MSM: men-who-have-sex-with-men
IDU: injective drug user
doi:10.1371/journal.pone.0125837.t001
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included in 1997–2000, 42 in 2001–4, 55 in 2005–8 and 64 in 2009–12. The proportion of pa-
tients with PHI out of the total of newly HIV-diagnosed patients increased over the time and
was 2.18%, 3.82%, 4.15% and 4.55% for the 4 periods, respectively (p = 0.005).
Genotypic drug resistance
According to the WHO list of mutations, 9% of patients had a strain with 1 or more resistance
mutations. The prevalence of TDR in patients with acute or recent HIV-1 infection decreased
until the period 2005–8, and slightly increased in 2009–12. The proportion of resistance was
17.9% for the period 1997–2000, 9.5% for the period 2001–4, 3.6% for the period 2005–8 and
9.4% for the period 2009–12 (p = 0.2). The increase in the last period was found in nucleoside-re-
verse-transcriptase-inhibitor (NTRI) associated mutations (3.6% in 2005–8 and 4.7% in 2009–
12) and in protease inhibitor (PI) associated mutations (1.8% in 2005–8 and 4.7% in 2009–12).
Non-nucleoside reverse transcriptase inhibitor (NNRTI) associated resistance mutations, and re-
sistance mutations to more than one family, however, decreased in the last period (Fig 1A). Over-
all, there were no differences in rates of TDR between the MSM and the heterosexual population
(9.2% and 9.5% respectively, p = 0.628). There was no TDR among injection-drug-users (IDUs).
On the basis of the WHO proposed mutations, NRTI mutations were found in 11 patients
(5.8%), NNRTI mutations were found in 6 patients (3.2%) and PI mutations were found in 9
patients (4.8%). Resistance to at least 2 drugs from the different families was observed in 7 pa-
tients (3.7%). Some resistance mutations, such as Q151M or K65R, were not found. Details of
mutations found in each period are shown in Table 2. The E138A mutation, not listed by WHO
2009 list but associated to rilpivirine resistance was detected in 4 patients, 3 in the 2005–2008
period and 1 in the 2009–2012 period. No other rilpivirine associated mutation was detected.
HIV-1 Subtypes
Non-B subtypes were identified in 20 cases (10.6%). HIV-1 non-B subtype distribution in-
creased over the 4 periods: 0%, 4.8%, 9.1% and 20.3%, respectively, with a clear linear trend
(p = 0.01, Fig 1B). Both immigrant and non-B subtype proportions increased over the time
(Spearman’s Rank Correlation Coefficient = 0.8, p = 0.2). Non-B subtypes included subtypes
A, n = 1; C, n = 2; F, n = 2; G, n = 1; A/G recombinant, n = 1; B/G recombinants, n = 2; B/F re-
combinants, n = 3; CRF01_AE, n = 2; and other recombinants (B/C recombinant, B/
CRF06_cpx, CRF19_cpx (D segment), CRF02_AG/CRF09_cpx, CRF14_BG, CRF02_AG/Sub-
type B recombinant), n = 6 (Fig 2). All the Subtype F, B/G recombinants and B/F recombinants
were reported in the last period (2009–2012).
The proportion of males was comparable between patients with subtype B and non-B
(92.9% vs. 90%; p = 0.647), but regarding the route of transmission, MSMs were significantly
higher among patients with B subtype (82.8% vs. 65%) and heterosexuals among those with
non-B subtypes (20% vs. 10.1%; p = 0.001). There were no IDUs infected with non-B subtypes.
The proportion of immigrants was not different among patients infected with B and non-B
subtypes (30.8% and 35% respectively, p = 0.524). Patients infected by a non-B subtype were
slightly older (36 vs. 33 years old) and age categories differently distributed (p = 0.037). Finally,
TDR mutations were found in similar proportions among patients infected with subtype B and
non-B strains (8.9% and 10% respectively, p = 0.697). A comparison of patients infected with B
and non-B subtypes is shown in Table 3.
Discussion and Conclusions
In this study, the prevalence of TDR for antiretroviral drugs in patients with acute or recent
HIV-1 infection (less than 6 months) in a single reference center in Barcelona over a period of
Transmission of HIV-1 Drug Resistance and Non-B Subtypes in Barcelona
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Fig 1. Fig 1A: Prevalence of transmitted drug resistance mutations by study period and drug family
according to the 2009WHO list. Fig 1B: Prevalence of non-B HIV-1 subtypes and immigrants by study period.
Footnote figure: NRTI indicates nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse
transcriptase inhibitor; PI, protease inhibitor.
doi:10.1371/journal.pone.0125837.g001
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16 years (1997–2012) was 9%. In a meta-analysis including 26 studies performed in Spain [13],
those performed between 1996–2003 reported prevalence values of TDR that decreased from
26.7% to 6.7%. This wide range can be explained by differences in methodology. However, data
from the studies performed between 2004–8 showed a narrower range: 11% to 2.9%[13]. De
Mendoza et al. showed a decrease in the prevalence of resistance in PHI in other Spanish cities
from 20% in 1999 to 3.4% in 2001 [14]. The authors claimed that these changes were due to the
decrease in the number of patients with detectable viremia due to HAART and to the increase
in new infections transmitted by immigrants from areas with no access to ART (many of
whom were carrying HIV-1 non-B infections)[14]. However, access to ART has increased in
developing countries. This is consistent with our results up to 2008, but we noticed a new in-
crease in overall TDR in the last period (2009–12), although this increase was only seen for
some antiretroviral families (PI and NRTI), while NNRTI TDR and multi-drug resistance
transmission decreased. However, the increased single PI resistance mutations have very limit-
ed clinical consequences, considering the high genetic barrier of these drugs. A boosted-PI regi-
men is the regimen of choice when ART needs to be initiated in a patient with PHI and where
the resistance test is still unavailable [15]. Moreover, we found the E138A mutation, associated
with reduced susceptibility to rilpivirine in 4 patients of our cohort. This is related to the
Table 2. Details of mutations found according to antiretroviral family and period of study.
Period
Mutations N (%)* total 1997–2000 2001–2004 2005–2008 2009–2012
189 28 42 55 64
NRTI
M41L 6 (3.2) 2 (7.1) 2 (4.8) 0 (0) 2 (3.1)
D67N 3 (1.6) 1 (3.6) 0 (0) 1 (1.8) 1 (1.6)
T69N 2 (1.1) 1 (3.6) 0 (0) 0 (0) 1 (1.6)
K70R 2 (1.1) 2 (7.1) 0 (0) 0 (0) 0 (0)
M184V 1 (0.5) 1 (3.6) 0 (0) 0 (0) 0 (0)
L210W 3 (1.6) 1 (3.6) 1 (2.4) 1 (1.8) 0 (0)
T215F/Y 3 (1.6) 2 (7.2) 1 (2.4) 0 (0) 0 (0)
T215S/D/L 2 (1.1) 0 (0) 0 (0) 2 (3.6) 0 (0)
K219E/Q 4 (2.2) 2 (7.2) 0 (0) 1 (1.8) 1 (1.6)
NNRTI&
K101E 1 (0.5) 0 (0) 1 (2.4) 0 (0) 0 (0)
K103N 3 (1.6) 1 (3.6) 1 (2.4) 0 (0) 1 (1.6)
Y181C 3 (1.6) 1 (3.6) 1 (2.4) 1 (1.8) 0 (0)
G190A 1 (0.5) 0 (0) 1 (2.4) 0 (0) 0 (0)
PI
M46I/L 5 (2.7) 2 (7.1) 2 (4.8) 0 (0) 1 (1.6)
I54L 1 (0.5) 1 (3.6) 0 (0) 0 (0) 0 (0)
V82A/F/I/T 7 (3.7) 3 (1.6) 2 (4.8) 0 (0) 2 (3.1)
L90M 2 (1.1) 0 (0) 1 (2.4) 1 (1.8) 0 (0)
* Only mutations found in at least one case according to WHO list of TDR are listed.
& E138A mutation, not listed by WHO 2009 list but associated to rilpivirine resistance was detected in 4 patients (2.1%), 3 (5.4%) in the 2005–2008 period
and 1 (1.6%) in the 2009–2012 period.
NRTI: Nucleoside/nucleotide reverse transcriptase inhinitors
NNRTI: Non-nucleoside reverse transcriptase inhibitors
PI: Protease inhibitors
doi:10.1371/journal.pone.0125837.t002
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Fig 2. Phylogenetic tree analysis of the non-B HIV-1 pol sequences. Footnote figure: The phylogenetic
inferences were performed by the Neighbor-Joining algorithm under the Kimura-2 parameter nucleotide
substitution model with bootstrap. HIV-1 pure subtype and CRFs reference sequences were obtained from
Los Alamos National Laboratory (LANL; www.hiv.lanl.gov). Bootstrap values of 70% or greater provide
reasonable confidence for genotype assignment (sequences represented in blue). Sequences represented in
red were suspected to be recombinants and re-analyzed by bootscanning (data not shown).
doi:10.1371/journal.pone.0125837.g002
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polymorphic nature of the mutation, since it was found in patients infected years before the the
drug became available. Indeed, prompt initiation of ART during PHI has not only clinical but
also epidemiological consequences: PHI patients are a significant source of HIV transmission
[16]. Thus early therapy may decrease transmissibility [15–17].
While some studies suggest that the prevalence of TDR mutations was decreasing in Spain
until 2009 [18], data published by Yebra et al.[19] for 354 HIV-1 infected patients diagnosed
between 1999 and 2007 in 4 Spanish HIV/AIDS clinics (3 in Madrid and 1 on the Canary Is-
lands) seems to contradict those results. The overall prevalence of TDR was 13.8%, and the au-
thors did not observe a decreasing temporal trend, but an increasing one. Moreover, they
found a significantly higher prevalence of NNRTI resistance mutations among patients in-
fected by non-B subtypes [19]. This must be considered in the context of the expansion of ART
access in developing countries, in which NNRTI-based regimens (particularly efavirenz) are
Table 3. Patients characteristics according to subtype of infection (B or non-B).
total B subtype Non-B subtypes p
N (%) 189 (100) 169 (89.4) 20 (10.6)
Gender* 0.647
Male 175 (92.6) 157 (92.9) 18 (90)
Female 14 (7.4) 12 (7.1) 2 (10)
Age** (n = 188) 33 (28–39) 33 (28–39) 36 (29–47) 0.037
<30* 63 (33.5) 58 (34.3) 5 (26.3)
30–40 82 (43.6) 77 (45.6) 5 (26.3)
40–50 33 (17.6) 27 (16) 6 (31.6)
>50 10 (5.3) 7 (4.1) 3 (15.8)
Route of transmission* 0.001
MSM-bisexual 153 (81) 140 (82.8) 13 (65)
Heterosexual 21 (11.1) 17 (10.1) 4 (20)
IDU 10 (5.3) 10 (5.9) 0 (0)
Unknown 5 (2.6) 2 (1.2) 3 (15)
Origin* 0.524
Native 120 (63.5) 107 (63.3) 13 (65)
Immigrant 59 (31.2) 52 (30.8) 7 (35)
Unknown 10 (5.3) 10 (5.9) 0 (0)
Symptomatic* 1
yes 162 (85.7) 145 (85.8) 17 (85)
no 27 (14.3) 24 (14,.2) 3 (15)
Plasma HIV-1 log10RNA** (n = 188) 5.17 (4.51–5.80) 5.17 (4.60–5.80) 5.50 (4.89–5.92) 0.533
<5.0* 78 (41.5) 71 (42.3) 7 (35)
>5.0 110 (58.5) 97 (57.7) 13 (65)
CD4 cell count/ul** (n = 188) 494 (375–619) 490 (380–614) 512 (372–619) 0.175
<350 45 (23.9) 39 (23.2) 6 (30)
350–500 52 (27.7) 50 (29.8) 2 (10)
>500 91 (48.4) 79 (47) 12 (60)
Resistant strain (any mutation)* 17 (9) 15 (8.9) 2 (10) 0.697
* n(%)
** median (IQR)
MSM: men-who-have-sex-with-men
IDU: injective drug user
doi:10.1371/journal.pone.0125837.t003
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the most frequently prescribed. The most recent results of the CoRIS Spanish Cohort found
7.9% of TDR according to the WHO list of mutations [20], which is consistent with our results.
The results of studies from France and Italy also showed a decrease until the early/mid-
2000s [21, 22]. However, in Germany and in France in more recent studies, TDR seems to be
stabilizing to levels comparable to our report in the last period (2009–12)[23, 24]. In Europe,
the most important data sets come from the SPREAD Programme, which prospectively investi-
gates TDR among patients with newly diagnosed HIV-1 infection in 20 European countries
and Israel. Data from 1996–2002 showed a prevalence of 13.5% among recently infected pa-
tients [25]. During the following study period, 2002–5, the prevalence seems to be stabilizing at
8.4%[26]. In a more recently published, large multi-cohort European study, TDR showed a rate
of around 10%[27]. These values are comparable with the 9% of global TDR found in our
study, and with the 9.4% of the last period.
Surveys in the United States report an increase in the prevalence of TDR rates during recent
years. In 2005 surveys, the TDR rates were 25%[5], while previous reports showed a rate of
8.3% for 1997–2001 (26). Little et al. reported an increase from 3.4% in 1995–8 to 12.4% in
1999–2000 in 10 US cities [28]. The National HIV Surveillance system reported TDR rates of
14.6% in 2006 [29] and 16% in 2007 for 10 states and 1 county in the US [30]. In a more recent
study performed in New York City in patients with acute or recent infection (median 66.5
days), TDR prevalence was 14.3%[31]. Rates can be influenced by different definitions and
methodologies, but resistance could also vary according to demographic factors and access to
health care and antiretroviral treatment. The US Surveillance study performed in 2006 showed
that the prevalence of mutations varied with ethnicity and risk behavior: 14% in white MSM
compared with less than 5% in Hispanic or African-American heterosexual men or African-
American women [32], probably due to differences in access to health care in the US [33]. In
Catalonia, the health care system is universal and free and provides ART to all those who need
it, reducing the impact of these differences. In our cohort, we did not observe resistance in
IDUs. Possible explanations are that IDUs are being infected by individuals not exposed to
ART and that this transmission route is becoming less frequent. Indeed, there were no patients
with PHI who had acquired the HIV infection through injection use in the last period (2009–
12) of our study. However, the descriptive design and the small number of patients in this
study prevent us from drawing definite conclusions for this risk group of patients.
Resistance mutations may persist for a variable time following transmission [34, 35]. Never-
theless, NRTI-associated mutations can gradually disappear, particularly those reducing viral
fitness (such as M184V). A study performed in the framework of the Swiss HIV Cohort Study
found that M184V minority variants were present in 8.2% of acute/recently infected patients
and only in 2.5% of chronic/established infections [36]. Thus, the timing of the genotypic test
may also explain differences in detected rates both in European and American studies.
Non-B subtype infections account for 20–40% of new HIV diagnoses in some European
countries [37–39]. It is noteworthy that, in our study, no cases of infection by these HIV-1 non-
B variants were reported in 1997, and they then progressively increased with time. A retrospec-
tive Spanish study performed outside Catalonia from 1995 to 2003 found that non-B subtypes
were recognized in 43.2% of HIV-1-infected subjects with epidemiological suspicion of infec-
tion by non-B subtypes [40]. In another Spanish study including 198 seroconverters from dif-
ferent cities outside Catalonia, between 1997 and 2004, the frequency of non-B subtype HIV
infections was only 7.6%, and no cases were found before 2002 [6]. Another region with high
rates of non-B HIV infections is Galicia (a province with predominantly Portuguese and Afri-
can immigration)[41]. Indeed, Pernas et al. recently reported a 37.8% of non-B variants in
northwest Spain, and subtype F was the most prevalent. These patients may also have and im-
paired virological response [42]. In our report, we found an increasing trend over time of non-B
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subtype HIV infections in Barcelona. B/F recombinants, B/G recombinants and subtype F were
exclusively found in the last period. The MSM population, which represented almost 90% of the
cases of PHI in our study in the last period (2009–12), seems to be particularly affected by this
emergence. Indeed, although MSM was the most prevalent risk factor in all periods, the propor-
tion among the total patients with PHI increased over time, suggesting a clear issue of transmis-
sion in early phases of HIV infection in this group. A correlation was observed between the
increase in immigration and the increase in non-B subtypes. Therefore, it may be hypothesized
that immigrants are infected locally by B subtypes, whereas Spanish-born patients become in-
fected by non-B subtypes during sexual contact with immigrants infected by non-B variants.
Our study has several limitations. First, the limited number of patients infected by intrave-
nous drug use limits the extrapolation of our conclusions. Second, the fact that some mutations
are identified as resistant does not necessarily indicate clinical resistance. Last, the number of
patients included per period progressively increased. A small bias in selection criteria for recent
infection (within the 180-day period) cannot completely been excluded, which might have re-
duced the detection of some resistance mutations in a determined period. The study does, how-
ever, have several strengths. The number of patients with PHI included is very large for a
single-center study. It has been performed over a long period of time, allowing us to analyze
also epidemiological and risk trends in a longitudinal way.
Antiretroviral resistance is a frequent, dynamic, and complex phenomenon that should be
considered from both individual and public health perspectives. The heterogeneous nature of
data might be due to temporal and geographic variations, differences in the resistance tests
used, timing of sampling, local prevalence of HIV subtypes, and scarce access to health care. It
is necessary to establish a consensus regarding the definition of a resistance mutation and re-
cent HIV infection in order to ensure the quality and comparative value of data.
In conclusion, the overall prevalence of resistant HIV-1 strains in acute and recent HIV-
1-infected patients in Barcelona was 9%. Non-B subtypes are emerging in our population and
the proportion of immigrants among patients with acute or recent HIV infection is increasing.
These data should be taken into account when starting combined antiretroviral therapy in this
setting and in the development of strategies for the prevention of HIV transmission, particular-
ly in groups such as MSM.
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